259 related articles for article (PubMed ID: 25432571)
1. Treatment of chronic pulmonary aspergillosis with voriconazole: review of a case series.
Cucchetto G; Cazzadori A; Conti M; Cascio GL; Braggio P; Concia E
Infection; 2015 Jun; 43(3):277-86. PubMed ID: 25432571
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of voriconazole in the treatment of chronic pulmonary aspergillosis: experience in Japan.
Saito T; Fujiuchi S; Tao Y; Sasaki Y; Ogawa K; Suzuki K; Tada A; Kuba M; Kato T; Kawabata M; Kurashima A; Sakatani M;
Infection; 2012 Dec; 40(6):661-7. PubMed ID: 22956473
[TBL] [Abstract][Full Text] [Related]
3. Twelve-month clinical outcomes of 206 patients with chronic pulmonary aspergillosis.
Bongomin F; Harris C; Hayes G; Kosmidis C; Denning DW
PLoS One; 2018; 13(4):e0193732. PubMed ID: 29634721
[TBL] [Abstract][Full Text] [Related]
4. The clinical presentations of pulmonary aspergillosis in children with cystic fibrosis - preliminary report.
Walicka-Serzysko K; Sands D
Dev Period Med; 2015; 19(1):66-79. PubMed ID: 26003072
[TBL] [Abstract][Full Text] [Related]
5. Treatment of chronic pulmonary aspergillosis by voriconazole in nonimmunocompromised patients.
Camuset J; Nunes H; Dombret MC; Bergeron A; Henno P; Philippe B; Dauriat G; Mangiapan G; Rabbat A; Cadranel J
Chest; 2007 May; 131(5):1435-41. PubMed ID: 17400661
[TBL] [Abstract][Full Text] [Related]
6. Voriconazole for chronic pulmonary aspergillosis: a prospective multicenter trial.
Cadranel J; Philippe B; Hennequin C; Bergeron A; Bergot E; Bourdin A; Cottin V; Jeanfaivre T; Godet C; Pineau M; Germaud P
Eur J Clin Microbiol Infect Dis; 2012 Nov; 31(11):3231-9. PubMed ID: 22782438
[TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy of sequential therapy with voriconazole on COPD patients in acute phase with pulmonary aspergillosis and effects on cytokines and pulmonary functions.
Du JF; Chi YM; Song Z; Di QG; Shi J; Lv J; Mai ZT; Li M; Sun BH; Jiang MM
Eur Rev Med Pharmacol Sci; 2018 Mar; 22(6):1837-1842. PubMed ID: 29630134
[TBL] [Abstract][Full Text] [Related]
8. Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis.
Sambatakou H; Dupont B; Lode H; Denning DW
Am J Med; 2006 Jun; 119(6):527.e17-24. PubMed ID: 16750972
[TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics and treatment outcomes of chronic pulmonary aspergillosis.
Jhun BW; Jeon K; Eom JS; Lee JH; Suh GY; Kwon OJ; Koh WJ
Med Mycol; 2013 Nov; 51(8):811-7. PubMed ID: 23834282
[TBL] [Abstract][Full Text] [Related]
10. Assessment of posaconazole salvage therapy in chronic pulmonary aspergillosis using predefined response criteria.
Rodriguez-Goncer I; Harris C; Kosmidis C; Muldoon EG; Newton PJ; Denning DW
Int J Antimicrob Agents; 2018 Aug; 52(2):258-264. PubMed ID: 29906567
[TBL] [Abstract][Full Text] [Related]
11. Intrabronchial Voriconazole is a Safe and Effective Measure for Hemoptysis Control in Pulmonary Aspergilloma.
Mohan A; Tiwari P; Madan K; Hadda V; Poulose R; Bhalla AS; Khandelwal R; Khilnani GC; Guleria R
J Bronchology Interv Pulmonol; 2017 Jan; 24(1):29-34. PubMed ID: 27623423
[TBL] [Abstract][Full Text] [Related]
12. Isavuconazole and voriconazole for the treatment of chronic pulmonary aspergillosis: A retrospective comparison of rates of adverse events.
Bongomin F; Maguire N; Moore CB; Felton T; Rautemaa-Richardson R
Mycoses; 2019 Mar; 62(3):217-222. PubMed ID: 30570179
[TBL] [Abstract][Full Text] [Related]
13. Tolerability of oral itraconazole and voriconazole for the treatment of chronic pulmonary aspergillosis: A systematic review and meta-analysis.
Olum R; Baluku JB; Kazibwe A; Russell L; Bongomin F
PLoS One; 2020; 15(10):e0240374. PubMed ID: 33052954
[TBL] [Abstract][Full Text] [Related]
14. Serum Aspergillus fumigatus-specific IgG antibody decreases after antifungal treatment in chronic pulmonary aspergillosis patients.
Yao Y; Zhou H; Yang Q; Lu G; Yu Y; Shen Y; Zhou J
Clin Respir J; 2018 Apr; 12(4):1772-1774. PubMed ID: 28862383
[No Abstract] [Full Text] [Related]
15. Flucloxacillin Results in Suboptimal Plasma Voriconazole Concentrations.
Muilwijk EW; Dekkers BGJ; Henriet SSV; Verweij PE; Witjes B; Lashof AMLO; Groeneveld GH; van der Hoeven J; Alffenaar JWC; Russel FGM; van de Veerdonk F; Brüggemann RJM
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28717040
[TBL] [Abstract][Full Text] [Related]
16. The incidence of cutaneous squamous cell carcinoma in patients receiving voriconazole therapy for chronic pulmonary aspergillosis.
Kosmidis C; Mackenzie A; Harris C; Hashad R; Lynch F; Denning DW
Naunyn Schmiedebergs Arch Pharmacol; 2020 Nov; 393(11):2233-2237. PubMed ID: 32820348
[TBL] [Abstract][Full Text] [Related]
17. Characteristics and outcomes of chronic pulmonary aspergillosis: a retrospective analysis of a tertiary hospital registry.
Camara B; Reymond E; Saint-Raymond C; Roth H; Brenier-Pinchart MP; Pinel C; Cadranel J; Ferretti G; Pelloux H; Pison C;
Clin Respir J; 2015 Jan; 9(1):65-73. PubMed ID: 24406138
[TBL] [Abstract][Full Text] [Related]
18. Impact of high baseline Aspergillus-specific IgG levels on weight and quality-of-life outcomes of patients with chronic pulmonary aspergillosis.
Bongomin F; Garcez T; Denning DW
Med Mycol; 2020 Oct; 58(7):1000-1004. PubMed ID: 32343313
[TBL] [Abstract][Full Text] [Related]
19. Voriconazole and posaconazole improve asthma severity in allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization.
Chishimba L; Niven RM; Cooley J; Denning DW
J Asthma; 2012 May; 49(4):423-33. PubMed ID: 22380765
[TBL] [Abstract][Full Text] [Related]
20. [A clinican linical analysis of 29 cases of chronic pulmonary aspergillosis].
Xu LY; Lai GX; Hu Q; Zhang L; Liu DL; Zhu GB; Li XH; Shi HH; Xu C; Yu YH; Bao YW; Chen W
Zhonghua Jie He He Hu Xi Za Zhi; 2018 Feb; 41(2):100-104. PubMed ID: 29429215
[No Abstract] [Full Text] [Related]
[Next] [New Search]
